Clinical Trial Update: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of RO7248824 in participants with Angelman Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angelman Syndrome

Drugs mentioned

• RO7248824

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Angelman Syndrome | Phase 1 | Status: COMPLETED